Market Alert: US Sets Tariff Floor at 15% – Potentially Rising to 50% from 01 August 2025
ReNerve Limited (ASX: RNV), an innovator in peripheral nerve repair, has announced a strategic partnership with Berkeley Biologics to co-develop two tissue-based product lines, targeting dermal and amniotic applications. These products, approved for US markets, will enhance ReNerve’s offering in trauma, wound care, and reconstructive surgeries. Launches are slated for Q3 2025 and late 2025, respectively. The agreement includes a five-year renewable supply arrangement, with manufacturing to take place in California. These new lines will complement ReNerve’s existing NervAlign™ portfolio and leverage its current surgeon customer base. This collaboration aligns with ReNerve’s vision to offer complete surgical solutions and drive growth in the US$2.7 billion global tissue market. Having already achieved 38% revenue growth in FY24 and clinical success with the NervAlign® Nerve Cuff, ReNerve is well-positioned for accelerated expansion. A webinar led by Director Dr. Julian Chick is scheduled for 3 June 2025 to discuss this initiative.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
